Feasibility of two dose - dense FEC regimens with growth factor support for adjuvant therapy in patients with <font color="red">early_1</font> <font color="red">breast_1</font> <font color="red">cancer_1</font> <font color="red">:_1</font> results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) . 
<br>
<br> Addition of epirubicin to adjuvant chemotherapy can provide <font color="red">important_1</font> <font color="red">benefits_1</font> for patients with early breast cancer , but the optimal dose remains unclear . Further improvements can be achieved with <font color="red">dose_1</font> <font color="red">-_1</font> <font color="red">dense_1</font> <font color="red">regimens_1</font> <font color="red">,_1</font> <font color="red">but_1</font> <font color="red">densification_1</font> <font color="red">of_1</font> <font color="red">fluorouracil_1</font> <font color="red">/_1</font> <font color="red">epirubicin_1</font> <font color="red">/_1</font> <font color="red">cyclophosphamide_1</font> <font color="red">(_1</font> <font color="red">FEC_1</font> <font color="red">)_1</font> <font color="red">has_1</font> <font color="red">proved_1</font> <font color="red">difficult_1</font> <font color="red">,_1</font> with FEC(60 ) providing little benefit over standard chemotherapy and FEC(100 ) associated with <font color="red">toxicity_1</font> <font color="red">._1</font> We investigated the feasibility of two intermediate dose - dense FEC regimens . Patients were randomised to six cycles of FEC(75 ) or FEC(90 ) , with all three drugs given on day 1 of each 14-day cycle . Patients also received pegfilgrastim 6 mg as a single subcutaneous injection on day 2 of each cycle . The primary efficacy endpoint was the <font color="red">proportion_2</font> <font color="red">of_2</font> <font color="red">subjects_2</font> <font color="red">receiving_2</font> <font color="red">>_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">85%_1</font> <font color="red">relative_1</font> <font color="red">dose_1</font> <font color="red">intensity_1</font> and was achieved by 96% and 88% of patients in the FEC(75 ) and FEC(90 ) arms , respectively . Of 147 FEC(75 ) infusions , 4.1% <font color="red">were_1</font> <font color="red">delayed_1</font> <font color="red">,_1</font> while 9.8% of 143 FEC(90 ) infusions <font color="red">were_1</font> <font color="red">delayed_1</font> <font color="red">._1</font> The most common reasons for <font color="red">delay_1</font> were <font color="red">adverse_3</font> <font color="red">events_3</font> <font color="red">and_2</font> <font color="red">personal_3</font> <font color="red">/_3</font> <font color="red">logistical_3</font> <font color="red">reasons_3</font> <font color="red">._3</font> One dose reduction occurred during the study ( FEC(90 ) ) , related to <font color="red">diarrhoea_2</font> <font color="red">._2</font> <font color="red">Grade_3</font> <font color="red">3_3</font> <font color="red">-_3</font> <font color="red">4_3</font> <font color="red">haematological_4</font> <font color="red">toxicities_4</font> were reported in two patients in the FEC(90 ) arm . There were no incidences of <font color="red">febrile_4</font> <font color="red">neutropenia_4</font> during the study . The most common adverse events were <font color="red">increases_2</font> <font color="red">in_2</font> <font color="red">liver_5</font> <font color="red">enzymes_5</font> <font color="red">and_3</font> <font color="red">gastrointestinal_5</font> <font color="red">events_5</font> <font color="red">;_5</font> no event resulted in discontinuation . Only one patient ( FEC(90 ) ) experienced <font color="red">serious_1</font> <font color="red">adverse_2</font> <font color="red">events_2</font> <font color="red">(_2</font> <font color="red">vomiting_5</font> <font color="red">and_5</font> <font color="red">throat_5</font> <font color="red">oedema_5</font> <font color="red">)_5</font> <font color="red">._2</font> In conclusion , dose - dense FEC(75 ) and FEC(90 ) are feasible with pegfilgrastim support . These regimens are associated with a very low risk of <font color="red">Grade_3</font> <font color="red">3_3</font> <font color="red">-_3</font> <font color="red">4_3</font> <font color="red">toxicity_4</font> <font color="red">._4</font>